AURONA

This study will evaluate the safety and efficacy, measured by reaching complete or partial remission, of voclosporin for FSGS patients. The aim of this trial is to assess the efficacy of voclosporin (VCS) (a softgel capsule) in achieving complete or partial remission of proteinuria after 24 weeks of therapy in patients with focal segmental glomerulosclerosis (FSGS). Also, the team will assess the safety and tolerability of VCS over 24 weeks.

How To Contact a Study Center:

• Visit KidneyHealthGateway.com to see if you might be eligible and to contact a study site near you
• Visit the study website